
Arthritis Drug Shows Promise in Slowing Type 1 Diabetes Progression
A world-first human trial conducted by researchers at St Vincent's Institute of Medical Research in Melbourne has found that the rheumatoid arthritis drug baricitinib can effectively suppress the progression of type 1 diabetes. The trial showed that baricitinib, when initiated within 100 days of diagnosis, can preserve insulin production and reduce the need for insulin treatment. This breakthrough research offers hope for a disease-modifying treatment for type 1 diabetes and could potentially revolutionize its management.
